[Skip to Content]
[Skip to Content Landing]
Views 522
Citations 0
Invited Commentary
July 16, 2020

Treatment for a Subtype of Exudative Macular Degeneration—Another Mountain Climbed

Author Affiliations
  • 1Division of Ophthalmology, Department of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu
  • 2Hawaii Macula and Retina Institute, Aiea
  • 3The Eye Institute, Medical College of Wisconsin, Milwaukee
JAMA Ophthalmol. Published online July 16, 2020. doi:10.1001/jamaophthalmol.2020.2421

Polypoidal choroidal vasculopathy (PCV) is a subtype of exudative age-related macular degeneration (AMD) that is most prevalent in Asian populations but is becoming increasingly recognized in populations around the world.1-3 The importance of recognizing PCV is that it is a subtype of exudative AMD that has been associated with resistance to antivascular endothelial growth factor (anti-VEGF) injections, which has become standard treatment for most cases of active exudative AMD.1,2 Therefore, finding a good treatment option for PCV would benefit many patients around the world.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words